Clinical impact summary for brodalumab in psoriasis

Outcome measure	Evidence	Implications
Disease-oriented evidence
Inhibition of IL-17 signaling	In a Phase I clinical trial, improvements in lesional skin mRNA levels for a number of IL-17-modulated keratinocyte-derived factors and for cytokines known to be directly regulated by IL-17R, were reported	Successful treatment with reduction of inflammation and associated comorbidities
Patient-oriented evidence
Decrease of psoriasis severity Improvement of quality of life	In Phase I and II clinical trials, PASI reduction and DLQI improvement were observed	Efficacious and safe treatment of patients with moderate to severe forms of psoriasis
Economic evidence
	Limited data No prospective randomized economic trials	Economic benefits considering under-treatment with other therapies